ERBB2 and breast cancer: In a previous study [12], we developed and validated a novel prognostic model called the Breast Cancer Test (BCT) score to predict the risk of 10-year distant metastasis in patients with hormone receptor-positive, HER2-negative early breast cancer treated with hormone therapy alone.